Brain

Scientia Vascular Announces Leadership Transition: John Lippert to Assume CTO Role; Rick Randall Appointed as CEO and Chairman

WEST VALLEY CITY, Utah, Jan. 13, 2025 /PRNewswire/ -- Scientia Vascular, a leading innovator in neurovascular medical devices, announces a strategic…

11 months ago

Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology…

11 months ago

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment PALO ALTO, Calif.,…

11 months ago

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a…

12 months ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

New Directors Bring Extensive Leadership Experience in Corporate Strategy and CommercializationSEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE)…

12 months ago

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and…

12 months ago

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to…

12 months ago

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) --…

12 months ago

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

12 months ago